Evidence map›Paper›PMID 40070614›Full record

ArticleCureus2025

Prevalence and Prognostic Value of Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease.

Evgeni V Mekov, Nikolay A Yanev, Nedelina Kurtelova, Teodora Mihalova, Adelina Tsakova, Yordanka Yamakova, Marc Miravitlles, Rosen E Petkov

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Evgeni V MekovDepartment of Pulmonary Diseases, Medical University - Sofia, Sofia, BGR.
Nikolay A YanevDepartment of Pulmonary Diseases, Medical University - Sofia, Sofia, BGR.
Nedelina KurtelovaDepartment of Pulmonary Diseases, Medical University - Sofia, Sofia, BGR.
Teodora MihalovaDepartment of Respiratory Diseases, Medical University - Sofia, Sofia, BGR.
Adelina TsakovaCentral Clinical Laboratory, Medical University - Sofia, Sofia, BGR.
Yordanka YamakovaDepartment of Anesthesiology and Intensive Care, Medical University - Sofia, Sofia, BGR.
Marc MiravitllesDepartment of Pneumology, Hospital Universitari Vall d'Hebron/Vall d'Hebron Institut de Recerca (VHIR) Vall d'Hebron Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, ESP.
Rosen E PetkovDepartment of Pulmonary Diseases, Medical University - Sofia, Sofia, BGR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction Pulmonary hypertension (PH) significantly influences chronic obstructive pulmonary disease (COPD) outcomes by exacerbating symptoms, increasing the frequency and severity of exacerbations, and contributing to higher hospitalization rates and mortality. Ultrasound assessment of mean pulmonary arterial pressure (PAPm) may contribute to the severity assessment of COPD. This study aims to assess the one-year prognostic value of PAPm at rest and after exercise in COPD patients. Methods This was an observational, prospective study of stable COPD patients over 40 years of age who were current or former smokers with a smoking history of >10 pack-years and a postbronchodilator FEV1 (forced expiratory volume in 1 second)/FVC (forced vital capacity) <0.7. Exclusion criteria were other significant lung diseases, systemic inflammatory diseases, or non-compliance with study procedures. PAPm was calculated using peak tricuspid regurgitation velocity via transthoracic echocardiography at rest and after a 6-minute walking test (6MWT) as a predictor of COPD exacerbations and death in one year. Patients were followed for 12 months to assess COPD exacerbations and mortality outcomes. Results A total of 96 patients were analyzed with a mean FEV1 (% predicted) of 55.8%. The prevalence of PH in this group was 52.1% (50/96). PAPm at rest was a stronger predictor of exacerbations, with an area under the curve (AUC) of 0.732, compared to PAPm after exercise (AUC: 0.700). The patients with PH had a significantly higher number of exacerbations (1.65 vs 0.89, p = 0.002). The patients with PAPm ≥30 after exercise also have a considerably higher number of exacerbations (1.64 vs. 1.1, p = 0.026). In univariate analysis, age, pack-years, FEV1, FVC, 6-minute walk distance (6MWD), COPD Assessment Test (CAT) score, previous exacerbations, PAPm, and PAPm after exertion are significant predictors for exacerbations and/or composite outcome (exacerbation or death). In multivariate analysis, however, only previous exacerbations remain significant in all models. Conclusion This study found a 52.1% prevalence of PH. Patients with PH at rest and after exercise had more frequent exacerbations during follow-up. Integrating non-invasive PAPm measurement into routine clinical practice could enhance risk stratification, guide treatment strategies, and improve patient outcomes.

Indexed as

comorbiditiescopdechocardiographyprevalencepulmonary hypertension

Identifiers

PMID40070614
PMCPMC11895804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.